Probucol normalizes cholesteryl ester transfer in type 2 diabetes

Highlights • Accelerated CET in T2D is proatherogenic. • Dysfunctional VLDL accelerates CET. • The antioxidant probucol corrects VLDL dysfunction. • Probucol normalizes CET in T2D. • Probucol may reduce cardiovascular risk in T2D.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2016-06, Vol.116, p.29-35
Hauptverfasser:	Bagdade, John D, Lane, James T, Subbaiah, P.V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anticholesteremic Agents - pharmacology Cardiovascular Diseases - metabolism Case-Control Studies CETP Cholesterol Esters - metabolism Cholesteryl ester transfer Diabetes Mellitus, Type 2 - metabolism Diabetic Angiopathies - metabolism Endocrinology & Metabolism Female Humans Lipid Metabolism - drug effects Lipoproteins, HDL - drug effects Lipoproteins, HDL - metabolism Lipoproteins, LDL - drug effects Lipoproteins, LDL - metabolism Lipoproteins, VLDL - drug effects Lipoproteins, VLDL - metabolism Male Middle Aged Probucol Probucol - pharmacology Risk Factors Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Accelerated CET in T2D is proatherogenic. • Dysfunctional VLDL accelerates CET. • The antioxidant probucol corrects VLDL dysfunction. • Probucol normalizes CET in T2D. • Probucol may reduce cardiovascular risk in T2D.
ISSN:	0168-8227 1872-8227
DOI:	10.1016/j.diabres.2016.04.020